Indivior (NASDAQ:INDV) Director Keith Humphreys Purchases 775 Shares

Indivior PLC (NASDAQ:INDV) Director Keith Humphreys acquired 775 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were bought at an average cost of $35.39 per share, with a total value of $27,427.25. Following the completion of the acquisition, the director directly owned 5,802 shares in the company, valued at approximately $205,332.78. This represents a 15.42% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Indivior Trading Down 1.0%

Shares of NASDAQ:INDV traded down $0.35 during mid-day trading on Wednesday, hitting $35.85. 1,097,072 shares of the company traded hands, compared to its average volume of 1,460,802. The stock has a market cap of $4.48 billion, a P/E ratio of 38.96 and a beta of 0.75. The stock has a 50-day moving average price of $33.69 and a two-hundred day moving average price of $25.59. Indivior PLC has a 12-month low of $7.62 and a 12-month high of $38.00.

Indivior (NASDAQ:INDV) last posted its quarterly earnings data on Thursday, October 30th. The company reported $0.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.34. Indivior had a net margin of 9.83% and a negative return on equity of 90.79%. The firm had revenue of $314.00 million for the quarter, compared to the consensus estimate of $257.66 million. As a group, analysts expect that Indivior PLC will post 1.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on INDV shares. Piper Sandler reaffirmed an “overweight” rating and set a $41.00 price target (up from $27.00) on shares of Indivior in a research report on Friday, October 31st. Morgan Stanley reiterated an “overweight” rating and set a $36.00 target price on shares of Indivior in a research note on Wednesday, December 3rd. Zacks Research raised shares of Indivior from a “hold” rating to a “strong-buy” rating in a report on Monday, November 3rd. HC Wainwright raised their price objective on shares of Indivior from $28.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Finally, Craig Hallum reaffirmed a “buy” rating and issued a $41.00 price objective on shares of Indivior in a research report on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, Indivior presently has a consensus rating of “Buy” and a consensus price target of $32.71.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. increased its holdings in Indivior by 16.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,820 shares of the company’s stock worth $71,000 after acquiring an additional 666 shares during the last quarter. GAMMA Investing LLC boosted its position in Indivior by 544.6% during the fourth quarter. GAMMA Investing LLC now owns 1,199 shares of the company’s stock worth $43,000 after purchasing an additional 1,013 shares during the period. CWM LLC purchased a new position in shares of Indivior in the third quarter worth about $25,000. Quarry LP bought a new stake in shares of Indivior in the third quarter valued at approximately $26,000. Finally, Raymond James Financial Inc. bought a new stake in shares of Indivior in the second quarter valued at approximately $26,000. Institutional investors own 60.33% of the company’s stock.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.